Streetbeat News

HRMY

Harmony Biosciences Holdings, Inc.

https://www.harmonybiosciences.com

Industry

Biotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Open

33.00

Mkt cap

1.9B

Volume

328K

High

33.18

P/E Ratio

15.56

52-wk high

41.61

Low

32.42

Div yield

N/A

52-wk low

27.14

Levi & Korsinsky has initiated an investigation into Harmony Biosciences Holdings, Inc. for potential violations of federal securities laws, following a report by Scorpion Capital raising concerns about Harmony's narcolepsy drug, Wakix.

Portfolio Pulse from

November 19, 2024 | 12:45 pm

Levi & Korsinsky has initiated an investigation into Harmony Biosciences Holdings, Inc. for potential securities fraud violations. This follows a report by Scorpion Capital raising concerns about Harmony's narcolepsy drug, Wakix.

Portfolio Pulse from

November 18, 2024 | 12:45 pm

Levi & Korsinsky has initiated an investigation into Harmony Biosciences Holdings, Inc. (HRMY) for potential securities fraud. This follows a report by Scorpion Capital raising concerns about Harmony's narcolepsy drug, Wakix.

Portfolio Pulse from

November 15, 2024 | 12:45 pm

Portfolio Pulse from

November 14, 2024 | 12:45 pm

Levi & Korsinsky has initiated an investigation into Harmony Biosciences Holdings, Inc. for potential federal securities law violations. This follows a report by Scorpion Capital raising concerns about Harmony's narcolepsy drug, Wakix.

Portfolio Pulse from

November 13, 2024 | 12:45 pm

Harmony Biosciences Holdings, Inc. is under investigation by Levi & Korsinsky for potential securities law violations related to its narcolepsy drug, Wakix. This follows a report by Scorpion Capital raising concerns about the drug.

Portfolio Pulse from

November 12, 2024 | 12:45 pm

Harmony Biosciences Holdings, Inc. is planning to file a supplemental New Drug Application (sNDA) for WAKIX to target idiopathic hypersomnia by Q4 2024. The company reported Q3 2024 net sales of $186 million for WAKIX and has surpassed $2 billion in cumulative net product revenue in less than five years.

Portfolio Pulse from

November 11, 2024 | 10:15 pm

Portfolio Pulse from

November 11, 2024 | 12:45 pm

Levi & Korsinsky has initiated an investigation into Harmony Biosciences Holdings, Inc. for potential securities fraud. This follows a report by Scorpion Capital raising concerns about Harmony's narcolepsy drug, Wakix.

Portfolio Pulse from

November 08, 2024 | 12:45 pm

Portfolio Pulse from

November 07, 2024 | 12:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.